The Patent Finder

Biosante Pharmaceuticals, Inc.

Also on record
Records under this name other than patents Biosante Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Biosante Pharmaceuticals, Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,919,079Cancer Immunotherapy Compositions and Methods of Use
Formerly held
In force
 · High confidence
In forceHigh confidence
US 8,580,247PS-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 7,901,902Methods and Compositions for Identifying a Cellular Immune Response Against Prostate Cancer
Formerly held
In force
 · High confidence
In forceHigh confidence
US 9,669,081Methods and Compositions for Treating Prostate Cancer or Inducing a Humoral Immune Response Against Prostate Cancer
Formerly held
In force
 · High confidence
In forceHigh confidence
US 8,840,881Methods and Compositions for Treating Prostate Cancer or Inducing a Humoral Immune Response Against Prostate Cancer
Formerly held
Lapsed on the fee record
Ended Sep 23, 2026 · High confidence
Lapsed on the fee recordEnded Sep 23, 2026High confidence
US 8,647,665Methods of treating hot flashes with formulations for transdermal or transmucosal application
Formerly held
Lapsed on the fee record
Ended Feb 11, 2026 · USPTO record
Lapsed on the fee recordEnded Feb 11, 2026USPTO record
US 7,473,418Pan cancer oncolytic vectors and methods of use thereof
Formerly held
Term ended
Term ended Mar 9, 2025 · USPTO record
Term endedTerm ended Mar 9, 2025USPTO record
US 7,858,083Pan Cancer Oncolytic Vectors and Methods of Use Thereof
Formerly held
Term ended
Ended no later than Mar 9, 2025 · Low confidence
Term endedEnded no later than Mar 9, 2025Low confidence
US 8,268,346Methods of treating hot flashes with formulations for transdermal or transmucosal application
Formerly held
Lapsed on the fee record
Ended Sep 18, 2024 · USPTO record
Lapsed on the fee recordEnded Sep 18, 2024USPTO record
US 7,176,022Directly injectable formulations which provide enhanced cryoprotection of cell products
Formerly held
Term ended
Term ended Feb 27, 2024 · USPTO record
Term endedTerm ended Feb 27, 2024USPTO record
10 of 46 patents shown.
Pro members see all 46.
Pro members: see all 46 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited